These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28050790)

  • 1. First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
    Forero A; Bendell JC; Kumar P; Janisch L; Rosen M; Wang Q; Copigneaux C; Desai M; Senaldi G; Maitland ML
    Invest New Drugs; 2017 Jun; 35(3):298-306. PubMed ID: 28050790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.
    Dominguez GA; Condamine T; Mony S; Hashimoto A; Wang F; Liu Q; Forero A; Bendell J; Witt R; Hockstein N; Kumar P; Gabrilovich DI
    Clin Cancer Res; 2017 Jun; 23(12):2942-2950. PubMed ID: 27965309
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
    Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
    Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
    Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
    Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
    Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
    Shitara K; Satoh T; Iwasa S; Yamaguchi K; Muro K; Komatsu Y; Nishina T; Esaki T; Hasegawa J; Kakurai Y; Kamiyama E; Nakata T; Nakamura K; Sakaki H; Hyodo I
    J Immunother Cancer; 2019 Aug; 7(1):219. PubMed ID: 31412935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
    Smith DC; Chugh R; Patnaik A; Papadopoulos KP; Wang M; Kapoun AM; Xu L; Dupont J; Stagg RJ; Tolcher A
    Invest New Drugs; 2019 Aug; 37(4):722-730. PubMed ID: 30591982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Burvenich IJ; Lee FT; Guo N; Gan HK; Rigopoulos A; Parslow AC; O'Keefe GJ; Gong SJ; Tochon-Danguy H; Rudd SE; Donnelly PS; Kotsuma M; Ohtsuka T; Senaldi G; Scott AM
    Theranostics; 2016; 6(12):2225-2234. PubMed ID: 27924159
    [No Abstract]   [Full Text] [Related]  

  • 11. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
    Menke-van der Houven van Oordt CW; Gomez-Roca C; van Herpen C; Coveler AL; Mahalingam D; Verheul HM; van der Graaf WT; Christen R; Rüttinger D; Weigand S; Cannarile MA; Heil F; Brewster M; Walz AC; Nayak TK; Guarin E; Meresse V; Le Tourneau C
    Oncotarget; 2016 Nov; 7(48):80046-80058. PubMed ID: 27507056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
    Shapiro GI; Vaishampayan UN; LoRusso P; Barton J; Hua S; Reich SD; Shazer R; Taylor CT; Xuan D; Borghaei H
    Invest New Drugs; 2017 Jun; 35(3):315-323. PubMed ID: 28070718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
    Rosen LS; Wesolowski R; Baffa R; Liao KH; Hua SY; Gibson BL; Pirie-Shepherd S; Tolcher AW
    Invest New Drugs; 2020 Feb; 38(1):120-130. PubMed ID: 30887250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
    Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.
    Mateo J; Berlin J; de Bono JS; Cohen RB; Keedy V; Mugundu G; Zhang L; Abbattista A; Davis C; Gallo Stampino C; Borghaei H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1039-46. PubMed ID: 25212537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
    Hong DS; Bowles DW; Falchook GS; Messersmith WA; George GC; O'Bryant CL; Vo AC; Klucher K; Herbst RS; Eckhardt SG; Peterson S; Hausman DF; Kurzrock R; Jimeno A
    Clin Cancer Res; 2012 Aug; 18(15):4173-82. PubMed ID: 22693357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
    Sharma S; de Vries EG; Infante JR; Oldenhuis CN; Gietema JA; Yang L; Bilic S; Parker K; Goldbrunner M; Scott JW; Burris HA
    Invest New Drugs; 2014 Feb; 32(1):135-44. PubMed ID: 23589214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
    Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
    Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP
    Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.